The role of hypothalamic and neuroendocrine changes in the pathogenesis of huntington's disease - Current understanding and implications for future treatments

European Neurological Review

Volumn 5, Issue 2, 2010, Pages 49-53

  Petersén, Åsa ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Huntingtin; Huntington's disease; Hypothalamus; Orexin; Oxytocin

Indexed keywords

EID: 84858261239     PISSN: 17583837     EISSN: 17583845     Source Type: Journal    
DOI: 10.17925/enr.2010.05.02.49     Document Type: Article

References (93)

1. Novak MJ, Tabrizi SJ, Huntington's disease, BMJ, 2010;340:c3109.
2. Phillips W, Shannon KM, Barker RA, The current clinical management of Huntington's disease, Mov Disord, 2008;23(11):1491-504.
3. Sturrock A, Leavitt BR, The clinical and genetic features of Huntington disease, J Geriatr Psychiatry Neurol, 2010;23(4):243-59.
4. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, The Huntington's Disease Collaborative Research Group, Cell, 1993;72(6):971-983.
5. Imarisio S, Carmichael J, Korolchuk V, et al., Huntington's disease: from pathology and genetics to potential therapies, Biochem J, 2008;412(2):191-209.
6. Zuccato C, Valenza M, Cattaneo E, Molecular mechanisms and potential therapeutical targets in Huntington's disease, Physiol Rev, 2010;90(3):905-81.
7. Gusella JF, MacDonald ME, Huntington's disease: the case for genetic modifiers, Genome Med, 2009;1(8):80.
8. Weydt P, Soyal SM, Gellera C, et al., The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease, Mol Neurodegener, 2009;4:3.
9. Metzger S, Rong J, Nguyen HP, et al., Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease, Hum Mol Genet, 2008;17(8):1137-46.
10. Morrison P, Harding-Lester S, Bradley A, Uptake of Huntington disease predictive testing in a complete population, Clin Genet, Sept 6 2010; [Epub ahead of print].
11. Paulsen JS, Nehl C, Hoth KF, et al., Depression and stages of Huntington's disease, J Neuropsychiatry Clin Neurosci, 2005;17(4):496-502.
12. van Duijn E, Kingma EM, van der Mast RC, Psychopathology in verified Huntington's disease gene carriers, J Neuropsychiatry Clin Neurosci, 2007;19(4):441-8.
13. Kloppel S, Stonnington CM, Petrovic P, et al., Irritability in pre-clinical Huntington's disease, Neuropsychologia, 2010;48(2):549-57.
14. Paulsen JS, Hoth KF, Nehl C, et al., Critical periods of suicide risk in Huntington's disease, Am J Psychiatry, 2005;162(4):725-31.
15. Duff K, Paulsen JS, Beglinger LJ, et al., 'Frontal' behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness, J Neuropsychiatry Clin Neurosci, 2010;22(2):196-207.
16. Peavy GM, Jacobson MW, Goldstein JL, et al., Cognitive and functional decline in Huntington's disease: dementia criteria revisited, Mov Disord, 2010;25(9):1163-9.
17. Duff K, Paulsen JS, Beglinger LJ, et al., Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study, Biol Psychiatry, 2007;62(12):1341-6.
18. Arnulf I, Nielsen J, Lohmann E, et al., Rapid eye movement sleep disturbances in Huntington disease, Arch Neurol, 2008;65(4):482-8.
19. Emser W, Brenner M, Stober T, et al., Changes in nocturnal sleep in Huntington's and Parkinson's disease, J Neurol, 1988;235(3):177-9.
20. Videnovic A, Leurgans S, Fan W, et al., Daytime somnolence and nocturnal sleep disturbances in Huntington disease, Parkinsonism Relat Disord, 2009;15(6):471-4.
21. Wiegand M, Moller AA, Lauer CJ, et al., Nocturnal sleep in Huntington's disease, J Neurol, 1991;238(4):203-8.
22. Aziz NA, Anguelova GV, Marinus J, et al., Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease, Parkinsonism Relat Disord, 2010;16(5):345-50.
23. Aziz NA, Anguelova GV, Marinus J, et al., Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease, Eur J Neurol, 2010;17(8):1068-74.
24. Hurelbrink CB, Lewis SJ, Barker RA, The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease, J Neurol, 2005;252(6):642-7.
25. Morton AJ, Wood NI, Hastings MH, et al., Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease, J Neurosci, 2005;25(1):157-63.
26. Goodman AO, Murgatroyd PR, Medina-Gomez G, et al., The metabolic profile of early Huntington's disease - a combined human and transgenic mouse study, Exp Neurol, 2008;210(2):691-8.
27. Trejo A, Tarrats RM, Alonso ME, et al., Assessment of the nutrition status of patients with Huntington's disease, Nutrition, 2004;20(2):192-6.
28. Marder K, Zhao H, Eberly S, et al., Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants, Neurology, 2009;73(5):385-92.
29. Vonsattel JP, DiFiglia M, Huntington disease, J Neuropathol Exp Neurol, 1998;57(5):369-84.
30. Vonsattel JP, Myers RH, Stevens TJ, et al., Neuropathological classification of Huntington's disease, J Neuropathol Exp Neurol, 1985;44(6):559-77.
31. Rosas HD, Lee SY, Bender AC, et al., Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection", Neuroimage, 2010;49(4): 2995-3004.
32. Rosas HD, Liu AK, Hersch S, et al., Regional and progressive thinning of the cortical ribbon in Huntington's disease, Neurology, 2002;58(5):695-701.
33. Rosas HD, Salat DH, Lee SY, et al., Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity, Brain, 2008;131(Pt 4): 1057-68.
34. DiFiglia M, Sapp E, Chase KO, et al., Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain, Science, 1997;277(5334):1990-3.
35. Sathasivam K, Hobbs C, Turmaine M, et al., Formation of polyglutamine inclusions in non-CNS tissue, Hum Mol Genet, 1999;8(5):813-22.
36. van der Burg JM, Björkqvist M, Brundin P, Beyond the brain: widespread pathology in Huntington's disease, Lancet Neurol, 2009;8(8):765-74.
37. Hill JW, Elmquist JK, Elias CF, Hypothalamic pathways linking energy balance and reproduction, Am J Physiol Endocrinol Metab, 2008;294(5):E827-32.
38. Insel TR, The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior, Neuron, 2010;65(6):768-79.
39. Kishi T, Elmquist JK, Body weight is regulated by the brain: a link between feeding and emotion, Mol Psychiatry, 2005;10(2):132-46.
40. Kleinridders A, Konner AC, Bruning JC, CNS-targets in control of energy and glucose homeostasis, Curr Opin Pharmacol, 2009;9(6):794-804.
41. Morton GJ, Cummings DE, Baskin DG, et al., Central nervous system control of food intake and body weight, Nature, 2006;443(7109):289-95.
42. Swaab DF, Neuropeptides in hypothalamic neuronal disorders, Int Rev Cytol, 2004;240:305-75.
43. Aziz NA, Swaab DF, Pijl H, et al., Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications, Rev Neurosci, 2007;18(3-4):223-51.
44. Hult S, Schultz K, Soylu R, et al., Hypothalamic and Neuroendocrine Changes in Huntington's Disease, Curr Drug Targets, 2010;11(10):1237-49.
45. Petersén A, Björkqvist M, Hypothalamic-endocrine aspects in Huntington's disease, Eur J Neurosci, 2006;24(4):961-7.
46. Petersén A, Hult S, Kirik D, Huntington's disease - new perspectives based on neuroendocrine changes in rodent models, Neurodegener Dis, 2009;6(4):154-64.
47. Kremer HP, The hypothalamic lateral tuberal nucleus: normal anatomy and changes in neurological diseases, Prog Brain Res, 1992;93:249-61.
48. Kremer HP, Roos RA, Dingjan G, et al., Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease, J Neuropathol Exp Neurol, 1990;49(4):371-82.
49. Timmers HJ, Swaab DF, van de Nes JA, et al., Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients, Brain Res, 1996;728(2):141-8.
50. Aziz A, Fronczek R, Maat-Schieman M, et al., Hypocretin and melanin-concentrating hormone in patients with Huntington disease, Brain Pathol, 2008;18(4):474-83.
51. Petersén A, Gil J, Maat-Schieman ML, et al., Orexin loss in Huntington's disease, Hum Mol Genet, 2005;14(1):39-47.
52. Baumann CR, Hersberger M, Bassetti CL, Hypocretin-1 (orexin A) levels are normal in Huntington's disease, J Neurol, 2006;253(9):1232-3.
53. Björkqvist M, Petersén A, Nielsen J, et al., Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease, Clin Genet, 2006;70(1):78-9.
54. Gaus SE, Lin L, Mignot E, CSF hypocretin levels are normal in Huntington's disease patients, Sleep, 2005;28(12):1607-8.
55. Meier A, Mollenhauer B, Cohrs S, et al., Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease, Brain Res, 2005;1063(2):201-3.
56. Gabery S, Murphy K, Schultz K, et al., Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses, Acta Neuropathol, 2010;20(6):777-880.
57. Kosfeld M, Heinrichs M, Zak PJ, et al., Oxytocin increases trust in humans, Nature, 2005;435(7042):673-6.
58. Savaskan E, Ehrhardt R, Schulz A, et al., Post-learning intranasal oxytocin modulates human memory for facial identity, Psychoneuroendocrinology, 2008;33(3):368-74.
59. Calder AJ, Keane J, Young AW, et al., The relation between anger and different forms of disgust: implications for emotion recognition impairments in Huntington's disease, Neuropsychologia, 2010;48(9):2719-29.
60. Gray JM, Young AW, Barker WA, et al., Impaired recognition of disgust in Huntington's disease gene carriers, Brain, 1997;120(Pt 11):2029-38.
61. Hennenlotter A, Schroeder U, Erhard P, et al., Neural correlates associated with impaired disgust processing in pre-symptomatic Huntington's disease, Brain, 2004;127(Pt 6):1446-53.
62. Johnson SA, Stout JC, Solomon AC, et al., Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease, Brain, 2007;130(Pt 7):1732-44.
63. Montagne B, Kessels RP, Kammers MP, et al., Perception of emotional facial expressions at different intensities in early-symptomatic Huntington's disease, Eur Neurol, 2006;55(3):151-4.
64. Sprengelmeyer R, Schroeder U, Young AW, et al., Disgust in pre-clinical Huntington's disease: a longitudinal study, Neuropsychologia, 2006;44(4):518-33.
65. Sprengelmeyer R, Young AW, Calder AJ, et al., Loss of disgust. Perception of faces and emotions in Huntington's disease, Brain, 1996;119(Pt 5):1647-65.
66. Douaud G, Gaura V, Ribeiro MJ, et al., Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study, Neuroimage, 2006;32(4):1562-75.
67. Kassubek J, Juengling FD, Kioschies T, et al., Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study, J Neurol Neurosurg Psychiatry, 2004;75(2):213-20.
68. Paulsen JS, Hayden M, Stout JC, et al., Preparing for preventive clinical trials: the Predict-HD study, Arch Neurol, 2006;63(6):883-90.
69. Soneson C, Fontes M, Zhou Y, et al., Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis, Neurobiol Dis, 2010;40(3):531-43.
70. Politis M, Pavese N, Tai YF, et al., Hypothalamic involvement in Huntington's disease: an in vivo PET study, Brain, 2008;131(Pt 11):2860-9.
71. Blennow K, Hampel H, Weiner M, et al., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nat Rev Neurol, 2010;6(3):131-44.
72. Björkqvist M, Leavitt BR, Nielsen JE, et al., Cocaine- and amphetamine-regulated transcript is increased in Huntington disease, Mov Disord, 2007;22(13):1952-4.
73. Pae CU, Lee C, Paik IH, Therapeutic implication of cocaine- and amphetamine-regulated transcript (CART) in the treatment of depression, Med Hypotheses, 2007;69(1):132-5.
74. Stanek LM, Cocaine- and amphetamine related transcript (CART) and anxiety, Peptides, 2006;27(8):2005-11.
75. Wiehager S, Beiderbeck DI, Gruber SH, et al., Increased levels of cocaine and amphetamine regulated transcript in two animal models of depression and anxiety, Neurobiol Dis, 2009;34(2):375-80.
76. Aziz NA, Pijl H, Frölich M, et al., Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease, J Clin Endocrinol Metab, 2009;94(4):1223-8.
77. Björkqvist M, Petersén A, Bacos K, et al., Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease, Hum Mol Genet, 2006;15(10):1713-21.
78. Saleh N, Moutereau S, Durr A, et al., Neuroendocrine disturbances in Huntington's disease, PLoS One, 2009;4(3):e4962.
79. Gallagher P, Reid KS, Ferrier IN, Neuropsychological functioning in health and mood disorder: Modulation by glucocorticoids and their receptors, Psychoneuroendocrinology, 2009;34(Suppl. 1):S196-207.
80. Aziz NA, Pijl H, Frolich M, et al., Delayed onset of the diurnal melatonin rise in patients with Huntington's disease, J Neurol, Jun 9 2009; [Epub ahead of print].
81. Jordan SD, Könner AC, Brüning JC, Sensing the fuels: glucose and lipid signaling in the CNS controlling energy homeostasis, Cell Mol Life Sci, 2010;67(19):3255-73.
82. Lalic NM, Maric J, Svetel M, et al., Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion, Arch Neurol, 2008;65(4):476-80.
83. Popovic V, Svetel M, Djurovic M, et al., Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease, Eur J Endocrinol, 2004;151(4):451-5.
84. Aziz NA, Pijl H, Frölich M, et al., Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease, Eur J Neurol, 2010;17(2):280-8.
85. Aziz NA, Pijl H, Frölich M, et al., Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients, Clin Endocrinol (Oxf), 2010;73(2):206-11.
86. Mestre T, Ferreira J, Coelho MM, et al., Therapeutic interventions for disease progression in Huntington's disease, Cochrane Database Syst Rev, 2009(3):CD006455.
87. Mestre T, Ferreira J, Coelho MM, et al., Therapeutic interventions for symptomatic treatment in Huntington's disease, Cochrane Database Syst Rev, 2009(3):CD006456.
88. Boudreau RL, McBride JL, Martins I, et al., Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice, Mol Ther, 2009;17(6):1053-63.
89. Drouet V, Perrin V, Hassig R, et al., Sustained effects of nonallele-specific Huntingtin silencing, Ann Neurol, 2009;65(3):276-85.
90. DiFiglia M, Sena-Esteves M, Chase K, et al., Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits, Proc Natl Acad Sci U S A, 2007;104(43):17204-9.
91. Krishnan V, Nestler EJ, Linking molecules to mood: new insight into the biology of depression, Am J Psychiatry, Sept 15 2010; [Epub ahead of print].
92. Sargent BJ, Moore NA, New central targets for the treatment of obesity, Br J Clin Pharmacol, 2009;68(6):852-60.
93. Kremer HP, Roos RA, Dingjan GM, et al., The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease, Neurosci Lett, 1991;132(1):101-4.